Dimerix (ASX:DXB) says the first patients have been dosed in the India-based CLARITY 2.0 feasibility/Phase 3 study of DMX-200 as a potential new treatment for respiratory complications associated with COVID-19.
The company said multiple sites have been initiated in India following regulatory approval from the country’s regulatory agency and shipment of DMX-200 drug supply from its US-based manufacturer.
It said an interim safety analysis is planned after the first 80 patients recruited in India in the 600-patient study. This is expected to occur in the first quarter of 2022. The study also plans to recruit COVID-19 patients in Australia.
“Any new treatment for COVID-19 respiratory complications will be very much welcomed by patients, their families and the medical community. Inflammatory disease treatments such as DMX-200 hold significant potential to improve clinical response, survival and quality of life post-treatment, and we are looking forward to investigating this drug in patients,” said Professor Vivekanand Jha, principal investigator and executive director of the George Institute India.
